Question 1

What is Livagen?

Accepted Answer

Livagen is a synthetic tetrapeptide, Lys-Glu-Asp-Ala (KEDA), in the Khavinson short-peptide bioregulator series. PubMed-indexed reports describe it as derived from amino-acid analysis of liver peptide complexes and study it as a liver-associated bioregulator (e.g., PMID 32362099). On this platform it is handled strictly as a Research Use Only material.

Question 2

What mechanism is most studied?

Accepted Answer

The most-replicated observation is in vitro: in lymphocytes cultured from elderly donors, Livagen has been reported to decondense heterochromatin and reactivate ribosomal genes, which the authors interpret as epigenetic/chromatin modulation (According to PubMed: PMID 12533768, DOI 10.1023/a:1021924702103; PMID 15085253, DOI 10.1023/b:bebm.0000024393.40560.05). These are cell-culture observations, not clinical outcomes.

Question 3

Is the research in humans or animals?

Accepted Answer

It is preclinical. The human-relevant work is in vitro on cultured human-derived lymphocytes; other studies use rat hepatocytes, organotypic liver cultures, and whole rats. According to PubMed, no human clinical trials of Livagen were identified (the Clinical Trial/RCT filter returned zero records).

Question 4

How strong and independent is the evidence?

Accepted Answer

It is real and citable but limited. The literature is concentrated in two affiliated programs (the St. Petersburg Institute of Bioregulation and Gerontology and Tbilisi State University), largely in lower-impact or Russian-language journals, with limited independent replication and no published pharmacokinetics. It is best read as early, exploratory mechanistic research.

Question 5

Are dosing protocols established?

Accepted Answer

No validated human dosing exists. Amounts and concentrations reported in the research vary by experimental model and are not human dosing guidance; consult the protocol reference and product documentation. This is not medical advice.

Question 6

What is known about observed effects in research or safety?

Accepted Answer

No controlled human safety or pharmacokinetic data were identified, so an observed-effects profile from rigorous research is not established. The reported findings come from in vitro and animal models only.

Question 7

How should it be handled and stored, and what is its regulatory status?

Accepted Answer

Store the lyophilized peptide desiccated and protected from light, refrigerate reconstituted solutions, and follow the protocol reference and product documentation. It is not an approved drug or consumer product and is handled as Research Use Only, not intended for human or veterinary use.

Phase	Daily reference amount	Units / volume
Weeks 1–2	0.5 mg (500 mcg)	7.5 units (0.075 mL)
Weeks 3–4	1.0 mg (1000 mcg)	15 units (0.15 mL)
Weeks 5–6	1.5 mg (1500 mcg)	22.5 units (0.225 mL)
Weeks 7–12	2.0 mg (2000 mcg)	30 units (0.30 mL)

Livagen.

Calculated volume reference

Cited protocol & reconstitution guide